A week after announcing its acquisition of Imago Biosciences (IMGO), things are ... would put Merck stock at roughly $110.40. MRK Chart November 282022 Analysts are generally positive on the ...

Nov 21 (Reuters) - Merck & Co Inc (MRK.N), opens new tab said on Monday it will acquire cancer drug developer Imago BioSciences Inc (IMGO.O), opens new tab for a total equity value of $1.35 ...

Imago BioSciences becomes part of the Merck & Co., Inc. family for $1.35 billion. Imago BioSciences, Inc. will certainly strengthen Merck's position in hematology. Imago BioSciences' pipeline ...

Merck & Co. has agreed to buy blood-cancer biotech Imago BioSciences Inc. for $1.35 billion, the big drugmaker’s latest deal in search of new sources of sales. Under the terms, Merck said Monday ...

Imago Biosciences (US:IMGO) took center stage on Monday, rising 104.5% after noting it had received a takeover offer from pharmaceutical giant Merck (US:MRK) in a deal worth around $1.35 billion.

Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioSciences and its bomedemstat drug candidate for blood disorders.

Merck is acquiring Imago Biosciences for $1.35 billion Merck & Co., Inc. (NYSE:MRK) is set to acquire biopharmaceutical company Imago Biosciences Inc (NASDAQ:IMGO) in a cash deal worth $1.35 billion.

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc (IMGO). (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company ...

REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines ...

Within the last quarter, Imago BioSciences (NASDAQ:IMGO) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Imago BioSciences ...

(Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments.